Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2006 -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (545)	12/12/2006 8:30:23 AM
From: rkrw	Read Replies (3) \| Respond to of 592

No i'm not smarter than you. epix ceo was the one who cleaned up and turned around tktx. Their goal was to develop vasovist which hasn't worked out and find a bio to merge with. I bet on him. He's smarter than I am. :) epix was down for the year before today even though he found a good bio :-)

To: nigel bates who wrote (545)	12/12/2006 10:01:36 AM
From: dr.praveen	Read Replies (1) \| Respond to of 592

EPIX Pharmaceuticals to Conduct Review of Past Stock Option Practices Tuesday December 12, 9:51 am ET <Little mischief going on:-)> LEXINGTON, Mass., Dec. 12 /PRNewswire-FirstCall/ -- EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX - News) today announced that the company's board of directors has created a special board committee of independent directors to conduct a review of past stock option practices at the company. The committee of independent directors has retained outside legal counsel to assist in this matter. The company stated that this review was initiated on Friday, December 8, 2006 in response to a media inquiry it received on that same day. That inquiry included assertions relating to the exercise of stock options during and prior to 2002, by a former chief executive officer of the company, who left the company in 2005.